The selective MET inhibitor tepotinib could benefit up to half of patients with advanced or metastatic non-small-cell lung cancer with a MET exon 14 skipping mutation

Adding enzalutamide to androgen deprivation therapy significantly prolongs overall survival in men with nonmetastatic, castration-resistant prostate cancer and rapidly increasing PSA

The TERAVOLT consortium has identified patient- and treatment-related factors associated with an increased risk for death among thoracic cancer patients with COVID-19 infection

Cancer patients with COVID-19 have specific risk factors that may help contribute to a high rate of mortality

Patients with high-risk gastrointestinal stromal tumours benefit from 3 years of adjuvant imatinib

Alpelisib discontinuation rates in people with advanced HR-positive, HER2-negative breast cancer can be reduced with the use of a detailed adverse event management plan focusing on the most commonly occurring events

Phase III study data show no benefit of histology-tailored neoadjuvant chemotherapy over anthracycline plus ifosfamide in patients with localised high-risk soft tissue sarcoma of an extremity or the trunk wall

On-target adverse events associated with TRK inhibitor therapy may include weight gain and dizziness